Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
about
EET signaling in cancerHigh-throughput transcriptomic and RNAi analysis identifies AIM1, ERGIC1, TMED3 and TPX2 as potential drug targets in prostate cancerGetting personal with prostate cancer: adding new pieces to an incomplete jigsaw puzzle.PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cellsSerum levels of arachidonic acid metabolites change during prostate cancer progression.FABP7 and HMGCS2 are novel protein markers for apocrine differentiation categorizing apocrine carcinoma of the breast.Characterization of transcriptional changes in ERG rearrangement-positive prostate cancer identifies the regulation of metabolic sensors such as neuropeptide Y.Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress.A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.Selective inhibitors and tailored activity probes for lipoprotein-associated phospholipase A(2)Genome-wide association studies for fatty acid metabolic traits in five divergent pig populationsThe TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisKnocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to FlutamideStructure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors.Ion channels and transporters in cancer. 4. Remodeling of Ca(2+) signaling in tumorigenesis: role of Ca(2+) transport.Do atherosclerosis and obesity-associated susceptibility to cancer share causative link to oxLDL and LOX-1?Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.Molecular and diagnostic features of apocrine breast lesions.Drug discovery in advanced prostate cancer: translating biology into therapy.Selenium alters miRNA profile in an intestinal cell line: evidence that miR-185 regulates expression of GPX2 and SEPSH2.Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells.Potential for targeted therapy in prostate cancers with ERG abnormalities.Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.Influence of androgen deprivation therapy on choline PET/CT in recurrent prostate cancer.Interrogation of ERG gene rearrangements in prostate cancer identifies a prognostic 10-gene signature with relevant implication to patients' clinical outcome.A Single Nucleotide Polymorphism in HPGD Gene Is Associated with Prostate Cancer Risk.Domain retention in transcription factor fusion genes and its biological and clinical implications: a pan-cancer study.Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.Identification of the predictive genes for the response of colorectal cancer patients to FOLFOX therapy
P2860
Q28250730-EE5EF248-9188-4813-956F-2A823BE7AB97Q28480861-363B707E-BC06-452A-9E25-BFC9F0924071Q33351113-D429441F-C89F-41EE-92C6-B2CB9F8D656EQ33593900-FAA09A9D-FD78-4979-B307-A5FD4F926AFDQ34398467-6801BB28-FD80-4CBD-B4B2-A10E5380B35AQ34497523-1A3D8199-349A-4F4D-B628-C337DF8C837BQ34580034-2048CEE6-1AC9-43F3-B5FA-68F90C9AC75BQ35650902-521715F3-0F91-4726-B907-0CB27E5983FAQ35653860-504DA542-9990-497F-AFAB-34631E3B90F4Q35745448-872758F4-1394-47F7-B440-7EC2512BE586Q35873154-24D91FA6-E1B8-437F-85AA-ADB0DC9F8788Q36022437-CE0045D0-9E3F-4F27-8D34-15AD781E57C5Q36547608-52C5079E-D504-4B86-A09D-09FBFDBD1C34Q36819498-582A9847-2B51-4736-BAE3-DB79357865BDQ36899790-0E85E1E5-B8A9-4E80-9CEA-FCE92B784622Q37238762-DBDA15E3-19D9-4594-9BF9-8932C91A5B09Q37673073-1C1EDCBF-3C37-4797-B2A4-2A7AF9730A4AQ37877078-2EB98229-168B-4DCB-A89A-88A8D6686269Q37924631-26EF67E0-28B8-424F-9DBD-0B0E9161E9AEQ38042634-0FAF0684-0E60-4671-83C0-1509667F122AQ38537958-4834ED76-3444-4C54-B074-8D8C9A0F36E8Q38839110-F5E24212-6BEF-4539-9851-D6F44A2F4A3FQ39112107-53A2E07C-39B5-466C-AF34-1480B54AEA16Q39421660-A6190452-75BC-4443-927A-7F3638E7885CQ39445577-6F0437ED-51CD-448C-A659-66FB977E444FQ39501622-F604811A-8B48-495D-A69A-EE85D34DCE1FQ40028950-04B3B111-E87D-44CB-B31B-8C4150642ACCQ41134388-F86D6485-6811-498C-9056-2DB9199BDD7FQ45384878-C73F586C-655D-41DD-9BE7-68DD6FB28A9DQ45789503-B315EE09-8357-4B2B-B25C-301973978B39Q47098621-FB42A154-2ACE-4515-8472-D21BC1058E6FQ47164118-BC95749E-BE7D-4BA6-A299-08A1BBD477BFQ55343985-FAFAB917-9681-415F-B414-C2A91E9B468AQ57074537-76F83A9C-8E11-436F-B4CB-BC8FFFD11CE2
P2860
Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Arachidonic acid pathway membe ...... ic targets in prostate cancer.
@en
Arachidonic acid pathway membe ...... ic targets in prostate cancer.
@nl
type
label
Arachidonic acid pathway membe ...... ic targets in prostate cancer.
@en
Arachidonic acid pathway membe ...... ic targets in prostate cancer.
@nl
prefLabel
Arachidonic acid pathway membe ...... ic targets in prostate cancer.
@en
Arachidonic acid pathway membe ...... ic targets in prostate cancer.
@nl
P2093
P2860
P50
P1476
Arachidonic acid pathway membe ...... ic targets in prostate cancer.
@en
P2093
Frank Smit
Gerald Verhaegh
Jack Schalken
John-Patrick Mpindi
Kalle A Alanen
Kristiina Iljin
Paula Vainio
Santosh Gupta
Tuomas Mirtti
P2860
P304
P356
10.1016/J.AJPATH.2010.10.002
P407
P577
2011-02-01T00:00:00Z